ClinicalTrials.gg
Active, not recruitingNCT07232537Updated Oct 8, 2026

An Observational Study Called FINE-REAL Korea to Learn More About the Use of the Drug Finerenone in People With Chronic Kidney Disease and Type 2 Diabetes in a Routine Medical Care Setting in South Korea

An observational study in Chronic Kidney Disease and Type 2 Diabetes Mellitus, sponsored by Bayer. Active, not recruiting at 1 site in South Korea. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2026-10-08.

Sponsored by Bayer · Observational

How we know

Updated Oct 8, 2026Now Active, not recruitingEnrollment updatedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
529
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 49 studies in Renal Insufficiency, Chronic by Bayer — 4 open to participants now, 8 under way, 2 of them phase 3. Renal Insufficiency, Chronic · Bayer.

Enrollment
14th of 17
529 · median 4,613
Started
2025
with 2 others
Observational
17 of 49
3 open now
Registered
45th of 49
by date

Among the 49 studies in Renal Insufficiency, Chronic by Bayer, this one is the 14th largest by enrollment of the 17 observational ones that give a count, is one of 3 that started in 2025, is one of 17 observational ones, and was the 45th registered.

Renal Insufficiency, Chronic

3,098 studies on the registry are indexed under Renal Insufficiency, Chronic; 700 are open to participants now.

Browse Renal Insufficiency, Chronic studies →

Open to participants now

4 of the 49 studies in Renal Insufficiency, Chronic by Bayer are open now, in 12 countries. Recruiting first, the newest first:

By country, each count listing its studies:

All 4 open studies →

Who these studies take

Of the 434 Renal Insufficiency, Chronic studies recruiting now, 245 (56%) set no upper age limit and 110 (25%) stop at 75 or younger; 43 take children under 18; 80 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 49 studies in Renal Insufficiency, Chronic by Bayer, or all of them as a file.
02

Study summary

This is an observational study in which data from people with chronic kidney disease (CKD) and type 2 diabetes (T2D) who will be receiving finerenone are collected and studied.

Chronic kidney disease is a long-term condition where the kidneys gradually lose their ability to filter waste and extra water from the blood. Type 2 diabetes occurs when the body does not produce enough insulin or does not use it effectively, leading to high blood sugar levels that can harm the kidneys. As a result, CKD can develop as a complication of T2D.

The study drug, finerenone, is already approved for doctors to prescribe to patients with CKD and T2D.

Finerenone is a medication that works by blocking certain proteins known as mineralocorticoid receptors. An increased stimulation of these proteins is thought to damage the kidneys and the heart. By lowering their stimulation, finerenone reduces the risk of kidney disease progressively getting worse.

The main purpose of this study is to learn more about characteristics and treatment patterns of people with CKD and T2D who have recently started or will start finerenone treatment as prescribed by their doctor as part of their routine medical care in South Korea.

The FINE-REAL Korea study is designed to collect additional data on people with CKD and T2D who are treated with finerenone according to the approved product information, and it will work alongside the original FINE-REAL study (NCT05348733) to gather enough information for safety assessments in Korean population.

To achieve this, researchers will collect data on:

  • Clinical characteristics of participants, including their medical history related to CKD and T2D, blood pressure, and heart health.
  • Reasons for starting finerenone.
  • Reasons for stopping finerenone early.
  • The planned and actual duration of finerenone treatment.
  • The dosing of finerenone.
  • Other medications taken alongside finerenone.

The study will also monitor any medical problems (known as adverse events) that participants may experience during the study. All adverse events will be recorded, regardless of whether they are related to the treatment.

One specific concern is hyperkalemia, which refers to high potassium levels in the blood. This condition can occur when finerenone is used with certain blood pressure medications. Researchers want to understand how often hyperkalemia happens and whether it leads to:

  • Early discontinuation of finerenone treatment.
  • The need for dialysis, a procedure that filters waste from the blood.
  • Hospitalization for care.

Data for this study will be collected from medical records and through interviews conducted by study doctors during routine medical visits.

Participants will be involved in the study for up to 12 months, although this duration may be shorter if their finerenone treatment is stopped early.

03

Conditions studied

  • Chronic Kidney Disease
  • Type 2 Diabetes Mellitus
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

Participants with a diagnosed of CKD and T2D will be enrolled after the decision for treatment with finerenone has been made by the treating physician.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Adult female or male participant - All genders (≥18 years old)
  • Diagnosis of CKD associated with T2D based on assessment by physician
  • Treatment according to local marketing authorization, finerenone 20 or 10 mg. Treatment should have been started up to 8 weeks before or after the ICF is signed.
  • Decision to initiate treatment with finerenone must be made before ICF is signed

Exclusion criteria

Exclusion Criteria:

  • Participation in an trial at any time during the course of this study
  • according to the local label
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Investigational drug or device

A drug or device being studied in a clinical trial.

It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
529 participants (actual)
Patient registry
No

Groups and cohorts

  • Participants diagnosed with CKD and T2D

    Participants who are newly prescribed finerenone under routine treatment conditions.

    Drug: Kerendia (Finerenone, BAY94-8862)

Interventions

  • DrugFinerenoneStudies of FinerenoneFinerenone pageHow we knowJudged by ClinicalTrials.gg, not part of the registry record.

    Decision will be taken by the treating physician to initiate treatment with finerenone.

06

What researchers measure

Primary outcomes

  1. Descriptive analysis of clinical characteristics of participants with chronic kidney disease (CKD) and with type 2 diabetes (T2D)

    Time frame: Up to 12 months after start of finerenone

  2. Descriptive summary of reasons for introducing finerenone

    Time frame: Up to 12 months after start of finerenone

  3. Descriptive summary of reasons for discontinuation of finerenone

    Time frame: Up to 12 months after start of finerenone

  4. Planned and actual duration of treatment with finerenone

    Time frame: Up to 12 months after start of finerenone

  5. Planned and actual dosing of finerenone

    Time frame: Up to 12 months after start of finerenone

  6. Descriptive summary of secondary therapies used in participants with CKD and T2D

    Time frame: Up to 12 months after start of finerenone

Secondary outcomes

  1. Occurrence of adverse events (AEs)

    Including treatment emergent adverse events (TEAEs), adverse drug reactions (ADRs), unexpected AEs, unexpected ADRs, serious adverse events (SAEs), and serious adverse drug reactions (SADRs)

    Time frame: Up to 30 days after the final treatment with finerenone

  2. Occurrence of hyperkalemia

    Reported hyperkalemia leading to permanent study drug discontinuation, dialysis or hospitalization

    Time frame: Up to 30 days after the final treatment with finerenone

07

Study locations

1 site
  • Many Locations
    Multiple Locations, South Korea
08

References and documents

Individual participant data

Plan to share: No — Currently, there is no established plan for the sharing of Individual Patient Data (IPD) from this study. The availability of this study's data will later be determined according to Bayer's commitment to the EFPIA/PhRMA 'Principles for responsible clinical trial data sharing.' This pertains to the scope, timepoint, and process of data access. As such, Bayer commits to considering requests from qualified researchers for patient- / study-level clinical trial data, and documents from clinical trials involving medicines and indications approved in the US and EU. However, this commitment does not reflect an active IPD sharing plan. This applies to data on new medicines and indications that have been approved by the EU and US regulatory agencies on or after January 01, 2014. Researchers can use www.vivli.org to request access to IPD and documents from clinical studies to conduct research. Information on Bayer's criteria for listing studies is provided in the member section of the portal.

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Nov 2025 (actual). Primary completion is estimated for Sep 2027, 22 months after the start.

Of 51 industry-sponsored observational studies under Renal Insufficiency, Chronic, half reached primary completion within 29 months of starting (the median), counting those still running; a quarter within 17 and three quarters within 51. This study's planned 22 months is below that.

Counting every sponsor, half of 327 studies reached it within 45 months; a quarter within 22 and three quarters within 191.

How these figures are worked out, and which studies are left out of them.

Registered
Nov 14, 2025
First posted
Nov 18, 2025
StartActual
Nov 20, 2025
Primary completionEst.
Sep 30, 2027
CompletionEst.
Jan 28, 2028
Last update
Oct 8, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Status
Recruiting→Active, not recruiting
changed Oct 8, 2026
Enrollment
500 (estimated)→529 (actual)
Oct 8, 2026
Show all 1 update
  1. Oct 8, 2026
    Recruiting→Active, not recruiting
    Enrollment 500 (estimated)→529 (actual)
    + 3 other changes: verification date, contact details and site details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT07232537
Lead sponsor
Bayer
Responsible party
Sponsor
First posted
Nov 18, 2025
Start date
Nov 20, 2025
Primary completion
Sep 30, 2027 (estimated)
Completion
Jan 28, 2028 (estimated)
Last update
Oct 8, 2026

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is active, not recruiting, as verified in Oct 2026. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion